$15,000,000 CAPITAL INFUSION SPURS ACCELERATED GROWTH FOR HEPALIFE

HepaLife Technologies has  commenced funding under a $15,000,000 common stock purchase agreement with a single institutional investor. This event marks an important milestone for us, and permits us to move forward with our core research activities of developing a rapid-response cell-based avian flu vaccine, creating the first-of-its-kind artificial liver device and  developing proprietary in-vitro/toxicology and pre-clinical drug testing platforms.